R&D - Pipeline

Products and New Molecular Entities

Boehringer Ingelheim has brought a range of successful products from own drug discovery to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US Dollar or have blockbuster potential. Continuously, our improvement initiatives have increased our research productivity and have resulted in a well-balanced pipeline showing a substantial number of new molecular entities and a high share of products in late phase development.

Successful Products from our own Research & Development

Product name
First launch
Active ingredient
Indication
Pradaxa®

2010

 

 

2008

 

dabigatran

etexilate

Stroke Prevention in atrial fibrillation

 

 

Prevention of venous thromboembolic events (VTE) in adults

Spiriva®

Respimat Soft Mist™ Inhaler

 

Spiriva®

2007

 

 

 

 

2002

 

 

tiotropium

 

 

COPD

Micardis® 1998 telmisartan Essential hypertension

Sifrol® / Mirapex® /

Mirapexin®

2006

 

 

1997

 

pramipexole

Restless legs syndrome (RLS)

 


Parkinson's disease (PD)

Viramune® 1996 nevirapine HIV/AIDS

Promising Compounds in our Pipeline - Examples

Clinical phase Compound*
Indication
Therapeutic principle
Mode of action
Phase III Dabigatran etexilate (Pradaxa®)

Acute venous thrombo-embolism (VTE)/

Secondary VTE

Anticoagulation Oral direct inhibition of Thrombin
Phase III

Linagliptin

Diabetes mellitus
type II

 

DPP-IV antagonist
Dipeptidylpeptidase-IV inhibitor
Phase III BI 10773 Diabetes mellitus type II  SGLT-2-antagonist  Inhibition of glucose transporter-2
Phase III BI 201335 Hepatitis C Direct virus targeting small molecule Oral HCV NS3/4A protease
Phase III BIBF 1120 (Vargatef TM **)
Non-small cell
lung cancer (NSCLC)
Angiogenesis inhibition
Triple angiokinase inhibitor simultaneously blocks VEGFR, FGFR, PDGFR
Phase III

BIBF 1120

 

Ovarian cancer

 

Angiogenesis inhibition Triple angiokinase inhibitor simultaneously blocks VEGFR, FGFR, PDGFR
Phase III Afatinib Non-small cell
lung cancer (NSCLC)
Signal transduction inhibition
Dual irreversible EGFR/HER2 inhibitor
Phase III Afatinib Breast cancer Signal transduction inhibition Dual irreversible EGFR/HER2 inhibitor
Phase III BIBF 1120 Idiopathic Pulmonary Fibrosis (IPF) Anti-fibrotic kinase inhibition Anti-fibrotic kinase inhibitor
Phase II BI 207127 Hepatitis C Direct virus targeting small molecule Oral NS5B RNA-dependent
Phase II Volasertib

 

Variety of
cancer types
Cell-cycle kinase inhibition PLK-1 antagonist
Phase I New compound
Variety of
cancer types

Cell-cycle kinase inhibition

Mitotic checkpoint inhibitor
Phase I New compound Diabetes mellitus type II
11ß-HSD-1-antagonist
 

* These are investigational agents; their safety and efficacy have not yet been established.

** Planned Brand Name.

Status: April 2011

Oncology and white room

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player